GLP-1 and PCOS: What the Clinical Evidence Shows

Polycystic ovary syndrome (PCOS) affects roughly 10% of women of reproductive age. Its core pathology — insulin resistance and hyperandrogenism — is deeply intertwined with metabolic dysfunction. GLP-1 drugs address both. Here's what randomized trials and meta-analyses have found.

PCOS is the most common endocrine disorder in women of reproductive age, characterized by irregular menstrual cycles, excess androgen production, and polycystic ovaries. Up to 80% of women with PCOS have insulin resistance, and 40–80% have overweight or obesity. The metabolic overlap with GLP-1 drug targets is substantial: insulin resistance, visceral adiposity, chronic low-grade inflammation, and dyslipidemia are all central to both PCOS pathology and GLP-1 pharmacology.

Weight Loss and Metabolic Improvement

Multiple randomized trials have demonstrated that GLP-1 receptor agonists (liraglutide and semaglutide) produce significant weight loss in women with PCOS — typically 5–15% of body weight depending on the dose and duration. A meta-analysis of liraglutide trials in PCOS showed a mean weight reduction of approximately 5–6 kg over 12–26 weeks, with concurrent improvements in fasting insulin, HOMA-IR (a measure of insulin resistance), and lipid profiles.

These metabolic improvements matter for PCOS beyond weight: insulin resistance directly drives ovarian androgen production. By reducing insulin levels and improving insulin sensitivity, GLP-1 drugs address a root cause of the hormonal imbalance, not just a symptom.

Hormonal Effects: Androgens and Ovulation

Several studies have shown that GLP-1 treatment reduces total testosterone and free androgen index in women with PCOS. The mechanism is primarily indirect: reduced insulin levels decrease stimulation of ovarian androgen production (insulin acts synergistically with LH on theca cells). Some studies have also reported improvements in menstrual regularity and ovulation rates, though these findings are less consistent and come from smaller trials.

Importantly, GLP-1 drugs are not FDA-approved for PCOS or fertility treatment. Their use in this population is off-label, and women of reproductive age on GLP-1 medications should be aware of the "Ozempic babies" phenomenon — unplanned pregnancies resulting from restored ovulation in women who believed they were infertile due to PCOS-related anovulation.

Comparison to Metformin

Metformin has been the primary insulin-sensitizing drug used off-label in PCOS for decades. Head-to-head studies suggest that liraglutide produces greater weight loss and comparable or superior improvements in insulin resistance compared to metformin alone. Combination therapy (GLP-1 + metformin) may be more effective than either drug alone, though large-scale randomized trials specifically designed for PCOS outcomes with semaglutide or tirzepatide are still needed.